A warning letter to Mylan NV is yet another indication that in response to last year’s discovery of carcinogenic nitrosamines in active pharmaceutical ingredients for certain blood pressure medications, US Food and Drug Administration investigators are turning their attention further up the pharmaceutical supply chain.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?